Microbiome CDMO Market to Reach USD 2.05B by 2035 at 38.66% CAGR | Quintile Reports

NEW YORK - Feb. 2, 2026 - PRLog -- Quintile Reports has published a new in-depth market intelligence study titled "Live Biotherapeutic Products and Microbiome CDMO Market Size Estimation, Share & Future Growth Trends Analysis, 2026–2035", highlighting a transformational growth phase for the global microbiome contract development and manufacturing organization (CDMO) industry. According to the report, the global Live Biotherapeutic Products and Microbiome CDMO market is projected to grow from USD 78.05 million in 2026 to USD 2,050.55 million by 2035, registering a remarkable CAGR of 38.66% during the forecast period.

This rapid expansion is fueled by increasing investments in microbiome-based drug development, growing prevalence of chronic and gastrointestinal diseases, and rising demand for specialized CDMO services capable of handling live and anaerobic microorganisms. The report provides comprehensive analysis across key segments including Live Biotherapeutic Products (LBPs), microbiome therapeutics, probiotics, prebiotics, synbiotics, and microbiome-derived small molecules, along with detailed insights into process development, manufacturing, regulatory support, and stability testing services.

Get Full Read Here: https://www.quintilereports.com/industry-report/1110-live...

North America dominates the Live Biotherapeutic Products and Microbiome CDMO market due to advanced GMP infrastructure and strong regulatory clarity, while Europe and Asia Pacific are emerging as high-growth regions supported by government initiatives and expanding biotech ecosystems. The study also profiles leading industry players such as Lonza, Catalent, WuXi Biologics, Samsung Biologics, Thermo Fisher Scientific, and AGC Biologics, offering strategic insights into competitive positioning and capacity expansion.

Get Free Sample PDF Report: https://www.quintilereports.com/request-sample/1110-live-...

Designed for pharmaceutical companies, biotech firms, investors, and decision-makers, this report delivers actionable intelligence, long-term market forecasts, and country-level analysis to support strategic planning and investment decisions in the fast-evolving microbiome CDMO landscape.

Place Order: https://www.quintilereports.com/buy-now/?id=1110-live-biotherapeutic-products-and-microbiome-cdmo-market&license_type=su

Key Reasons to Acquire the Live Biotherapeutic Products And Microbiome CDMO Market Research Report:

• This report offers a comprehensive analysis of the Live Biotherapeutic Products And Microbiome CDMO market from 2017 to 2035, including market segments, current trends, estimations, and dynamics
• It also provides information on key drivers, restraints, and opportunities
• Porter's five forces analysis is used to assess the potency of buyers and suppliers, helping stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network
• The report includes an in-depth analysis of the Live Biotherapeutic Products And Microbiome CDMO market segmentation to identify prevailing market opportunities